Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222521 · ClinicalTrials.gov registry record · Phase 3
Insulin Glargine Vs Standard Insulin Therapy
A Phase 3 study of Cystic Fibrosis-related Diabetes, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00222521: Completed Phase 3 study of Cystic Fibrosis-related Diabetes, sponsored by University of Minnesota.
NCT00222521 is a Phase 3 study of Cystic Fibrosis-related Diabetes that has completed, run by University of Minnesota. The registered enrollment target is 20 participants, below the 106-participant average among 10 other Cystic Fibrosis-related Diabetes trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00222521, a Phase 3 study of Cystic Fibrosis-related Diabetes, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
Conditions Studied
Interventions
- DRUG Glargine insulin
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
What the finished NCT00222521 record still lists
NCT00222521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 106-participant average among 10 other Cystic Fibrosis-related Diabetes trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Cystic Fibrosis-related Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Glargine insulin is the first listed.
NCT00222521 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00222521 about?
NCT00222521 is a clinical study titled "Insulin Glargine Vs Standard Insulin Therapy". This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
What is the current status of trial NCT00222521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2003-04. Estimated completion is 2005-08.
What conditions does trial NCT00222521 study?
This clinical trial studies the following conditions: Cystic Fibrosis-related Diabetes.
What interventions are being tested in trial NCT00222521?
The interventions under investigation include: Glargine insulin (DRUG).
Who is sponsoring clinical trial NCT00222521?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00222521 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis-related Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00222521's enrollment target sits among peer trials
20 7th of 10 higher than 4 of 10 other Cystic Fibrosis-related Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis-related Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bionic Pancreas in CFRD
RECRUITING · Phase 3
-
Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis
RECRUITING · Phase 1
-
ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
-
FEED-Cystic Fibrosis (FEED-CF)
RECRUITING · NA
-
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia